Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Uscom will soon be adding a new device to its company portfolio after securing patent allowance in Europe and America for the next 20 years
  • The company’s yet-to-be-named device is able to read your heart’s blood flow and pressure using ultrasound technology
  • Unlike the new device, previously used methods such as catheters were found to be invasive
  • Uscom claims the device will allow for faster diagnosis of cardiac problems to save lives and improve health

Medical technology developer, Uscom has a new method for measuring your heart’s blood flow and pressure without invasive techniques.

Today, the company secured allowance for patenting the technology in America and Europe for the next 20 years.

“This technology is an important step forward for clinical medicine,” CEO Professor Rob Phillips said

The device works by being placed just under your adam’s apple and above your sternum. Using ultrasound technology, Uscom claims to read your heart’s blood flow and functioning patterns. The device is yet to be named.

“Cardiac volume and pressure loops are the ‘holy grail’ in cardiovascular physiology, but have only previously been available using invasive cardiac catheters and transducers with all their complications,” Professor Rob said.

By measuring patterns in your heart’s blood flow, Uscom can detect early signs of cardiac dysfunction in the patient. The non-invasive technique is aimed at speeding up diagnosis and ensuring faster management.

“This new non-invasive technology combines the clinical strengths of our sector leading USCOM 1A and the Uscom BP+, and will provide us with accurate and universally applicable clinical cardiovascular measures,” he said.

‘1A’ and ‘BP+’ are previously released medical devices by the company that created the foundation of the new technology as the patenting process continues. Both 1A and BP+ are used in reading cardiovascular health as well.

“The new monitoring should be feasible in newborns, children, adults, and in the elderly and will improve patient care and outcomes in heart failure, hypertension and sepsis,” Rob added.

“This patent provides us with commercial protection as we develop new life saving products for Uscom and grow long term shareholder value,” concluded Professor Rob.

Shares in UCM continue to trade for 13.5 cents today, unchanged from yesterday’s closing price. The company’s market cap is currently valued at $18.66 million.

UCM by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.